**Notice to Comply With Sequence Rules**

Application No.	Applicant(s)
09/635,974	TEUFEL, THOMAS
Examiner	Art Unit
Anne Holleran	1642

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 8230, May 1, 1990.

2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).

3. A copy of the "Sequence Listing" in Computer Readable Form (CRF) has not been submitted as required by 37 C.F.R. 1.821(e).

4. A copy of the "Sequence Listing" in Computer Readable Form (CRF) has been submitted. However, the content of the CRF does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."

5. The Computer Readable Form (CRF) that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute CRF must be submitted as required by 37 C.F.R. 1.825(d).

6. The paper copy of the "Sequence Listing" is not the same as the Computer Readable Form (CRF) of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).

7. Other: \_\_\_\_\_

**Applicant Must Provide:**

An initial or substitute copy of the CRF "Sequence Listing".

An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

A statement that the content of the paper and CRF copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216  
For CRF Submission Help, call (703) 308-4212  
PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200  
To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**




**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants : Thomas TEUFEL  
Serial No. : 09/635,974  
Filing Date : August 9, 2000  
For : TREATMENT OF HYPERPROLIFERATIVE DISEASES  
WITH EPIDERMAL GROWTH FACTOR RECEPTOR  
ANTAGONISTS

Group Art Unit : 1642  
Examiner : Anne L. Holleran  
Confirmation No. : 5643  
Attorney Docket No. : 11245/48601  
Customer No. : 26646

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the  
United States Postal Service with sufficient postage as first class mail in an  
envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria,  
VA 22313-1450 on August 24, 2004.

By: 

Lawrence P. Casson (Reg. No. 46,606)

**SUBMISSION OF**  
**SEQUENCE LISTING STATEMENTS**

SIR:

**STATEMENT UNDER 37 CFR §1.821(f)**

I hereby state that the information recorded in computer readable form is identical to the  
paper sequence listing.


**STATEMENT UNDER 37 CFR §1.821(g)**

I hereby state that the submission, filed in accordance with 37 CFR 1.821(g), does not  
include new matter.

Respectfully submitted,

KENYON & KENYON

By:

  
Lawrence P. Casson  
Reg. No. 46,606  
One Broadway  
New York, NY 10004  
(212) 425-7200 (Telephone)  
(212) 425-5288 (Facsimile)

Dated: August 24, 2004